GSK Closed the Nuvalent Deal on 15 July. Seven Days Later the FDA Approved the Drug.
- The FDA approved Jideytro (zidesamtinib), a selective ROS1 inhibitor, for adults with locally advanced or metastatic ROS1-positive NSCLC who have had a prior ROS1 kinase inhibitor. It is GSK’s first approved medicine in lung cancer.
- The approval landed ahead of the 18 September 2026 target action date, and follows Breakthrough Therapy and Orphan Drug designations.
- Based on the single-arm ARROS-1 phase 1/2 trial (n=117): objective response rate 44% (95% CI 34-53), with duration of response of 82% at six months and 69% at twelve, including in patients with brain metastases and ROS1 resistance mutations.
- Jideytro came with the Nuvalent acquisition, which GSK completed on 15 July 2026. Roughly 50,000 people worldwide are diagnosed with ROS1-positive NSCLC each year, often non-smokers in their forties and fifties.
Deal read
Count the days. GSK closed the Nuvalent acquisition on 15 July and had an FDA approval on 22 July, seven days later, and roughly two months ahead of the September action date. That is about as fast as an acquisition can validate itself, and it reframes what GSK paid for. This was not a bet on science, it was the purchase of a filed, designated, near-approved asset, and the premium bought certainty rather than optionality. GSK’s own chief scientific officer says as much, describing a strategy of acquiring assets with validated targets. Watch the next one: neladalkib for ALK-altered NSCLC has a 27 November 2026 decision date, from the same acquisition. If that clears too, GSK will have bought an entire lung-cancer franchise, approved, in under five months.